Ceritinib
Therapeutic Group
Anti-neoplasticsIndication Dosage
Ceritinib is a medication used to treat a specific type of lung cancer called "ALK-positive non-small cell lung cancer." It is prescribed to patients when their cancer has spread or hasn't improved with other treatments. Ceritinib works by blocking certain proteins in cancer cells, which can slow down or stop the growth of the cancer. Your doctor will determine if Ceritinib is the right treatment for you based on your individual medical condition.
Treatment Of Anaplastic Lymphoma Kinase (ALK)-positive Advanced Non-small Cell Lung Cancer Previously Treated With Crizotinib:
- Adult: 750 Mg Once Daily, Dose Should Be Taken At The Same Time Every Day, Temporary Dose Interruption Or Dose Reduction May Be Required Based On Tolerability; Consult Product Literature; Discontinue Treatment If Patient Unable To Tolerate At Least 300 Mg Daily
Content
- Tab: Ceritinib 150mg
Pregnancy
Avoid Unless Essential
Stability
- Tyrosine Kinase Inhibitor
Contra Indications
- Congenital Long Qt Syndrome
Precautions
- Congenital Long Qt Syndrome
Lactation
- Contraindicated. Discontinue Breast-feeding.
Side Effects
- Abdominal Pain
- Anaemia
- Bradycardia
- Constipation
- Decreased Appetite
- Diarrhea
- Dyspepsia
- Dysphagia
- Fatigue
- Gastro-oesophageal Reflux Disease
- Hyperglycaemia
- Hypophosphataemia
- Nausea
- Pericarditis
- Pneumonitis
- Qt-interval Prolongation
- Rash
- Renal Failure
- Renal Impairment
- Visual Disorders
- Vomiting.
- Rare: Hepatotoxicity
- Pancreatitis
- Interstitial Lung Disease